AS

AstraZeneca

Every trial this sponsor leads in the registry, and everything it has published.

3,235All trials
Recruiting195
Recruited236
Not yet recruiting27
By invitation1
Completed2,449
Stopped324
Other3

459 active · 14% of this sponsor’s registry footprint

Oncology283 trials
Respiratory32 trials
Immunology & Inflammation25 trials
Cardiovascular23 trials
Metabolic/Endocrine/Nutrition23 trials
Renal & Urology16 trials
Neurology13 trials
Infectious Disease7 trials

Not shown above: 12 Phase 1 healthy-volunteer trials and 11 trials whose condition matched no therapy area.

Trials by phase

Phase 11,307
Phase 2678
Phase 3906
Phase 4215
Unphased129

Pipeline by phase · 132 drugs in active development

Phase 3 · 50 drugs

Durvalumab42 trials · 2 recruitingest. Sept 2026
Datopotamab Deruxtecan15 trials · 7 recruitingest. Sept 2026
Volrustomig (MEDI5752)12 trials · 4 recruitingest. Oct 2026
Osimertinib11 trials · 2 recruitingest. Feb 2027
Rilvegostomig (AZD2936)11 trials · 9 recruitingest. Jul 2027
Tezepelumab11 trials · 6 recruitingest. Jan 2027
Elecoglipron10 trials · 9 recruitingest. Oct 2026
Surovatamig (AZD0486, AZD0486 IV)9 trials · 8 recruitingest. Feb 2028

Phase 2 · 20 drugs

AZD41443 trials · 2 recruitingest. Oct 2026
ALXN20302 trialsest. Oct 2027
AZD02922 trials · 2 recruitingest. Dec 2027
AZD77982 trials
Oleclumab2 trials
Acalabrutinib + R-CHOP standard of care1 trial · 1 recruitingest. Dec 2027
ALXN19201 trial · 1 recruitingest. Jul 2027
AZD11631 trial · 1 recruitingest. Nov 2027

Phase 1 · 49 drugs

AZD13902 trialsest. Apr 2028
AZD34702 trials · 2 recruitingest. Dec 2028
AZD54922 trials · 2 recruitingest. May 2027
AZD77602 trials · 2 recruitingest. Apr 2027
ALXN22301 trial · 1 recruitingest. Dec 2026
ALXN23501 trial · 1 recruitingest. Jan 2032
AZD0120 - Regimen 11 trial · 1 recruitingest. Dec 2028

Phase 4 · 13 drugs

Trastuzumab Deruxtecan17 trials · 5 recruitingest. Oct 2026
Acalabrutinib (ACP-196)16 trials · 3 recruitingest. Jan 2027
Olaparib (AZD2281)12 trialsest. Apr 2027
Ravulizumab9 trials · 6 recruitingest. Jun 2027
Anifrolumab (Medi-546)8 trials · 3 recruitingest. Nov 2026
Benralizumab6 trials · 2 recruitingest. Oct 2026
Budesonide/Albuterol3 trials · 2 recruitingest. Feb 2027
Acoramidis1 trial · 1 recruitingest. Mar 2028

Not counted above: 1 combination backbone (established drugs used alongside the assets) and 9 unphased interventions.

Active trials only, code names and brands merged. 2,449 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 5 of 10 curated

Non-small cell lung cancer (Oncology)52 trials · 16 recruiting · 21 drugs3.6% of landscape
Breast cancer (Oncology)40 trials · 13 recruiting · 15 drugs1.3% of landscape
Type 2 diabetes (Endocrinology)15 trials · 11 recruiting · 4 drugs1.6% of landscape
Multiple myeloma (Oncology)7 trials · 6 recruiting · 2 drugs0.9% of landscape
Obesity (Metabolic & Nutrition)4 trials · 2 recruiting · 3 drugs0.4% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon